Daily Endocrinology Research Analysis
Three impactful studies advance endocrine and metabolic medicine today: a nationwide cohort links multiple endocrine toxicities from immune checkpoint inhibitors to improved survival; a UK Biobank analysis shows steatotic liver disease elevates microvascular complication risk in type 2 diabetes independent of adiposity, partly mediated by glycemic control; and a Diabetes Care study validates glycated albumin and fructosamine as credible alternatives to HbA1c against CGM-defined hyperglycemia.
Summary
Three impactful studies advance endocrine and metabolic medicine today: a nationwide cohort links multiple endocrine toxicities from immune checkpoint inhibitors to improved survival; a UK Biobank analysis shows steatotic liver disease elevates microvascular complication risk in type 2 diabetes independent of adiposity, partly mediated by glycemic control; and a Diabetes Care study validates glycated albumin and fructosamine as credible alternatives to HbA1c against CGM-defined hyperglycemia.
Research Themes
- Endocrine toxicities of immunotherapy and survival outcomes
- Steatotic liver disease as a risk amplifier in type 2 diabetes complications
- Validation of alternative hyperglycemia biomarkers against CGM
Selected Articles
1. Multiple or Single Endocrine Abnormalities Associated with Immune Checkpoint Inhibitors.
In a nationwide Japanese claims cohort of 12,978 ICI-treated patients, endocrine immune-related adverse events (irAEs) occurred in 13.4%; multiple endocrine abnormalities were associated with the greatest survival benefit (aHR 0.39) compared with none. The most common combination was hypothyroidism plus adrenal insufficiency.
Impact: Links endocrine irAEs to improved survival with dose–response (multiple > single), informing risk–benefit discussions and endocrine surveillance in oncology.
Clinical Implications: Proactive screening and prompt hormone replacement for ICI-induced endocrinopathies should be prioritized; development of multiple endocrinopathies may serve as a prognostic marker of antitumor response.
Key Findings
- Among 12,978 ICI-treated patients, 12.0% developed a single endocrine abnormality and 1.4% developed multiple abnormalities.
- Multiple endocrine abnormalities were associated with lower mortality (aHR 0.39; 95% CI 0.28–0.54) compared with no endocrinopathy.
- Mortality was significantly lower in patients with multiple abnormalities than in those with a single abnormality (aHR 0.56; 95% CI 0.39–0.79).
- The most common combination was hypothyroidism plus adrenal insufficiency (1.3%).
Methodological Strengths
- Large nationwide cohort with 12,978 ICI recipients and multivariable adjustment including exposure intensity.
- Clear operationalization of endocrine events via hormone replacement initiation enabling time-to-event analyses.
Limitations
- Claims-based definitions cannot distinguish central versus primary hormone defects and risk misclassification.
- Residual confounding by tumor biology and treatment selection cannot be fully excluded in observational design.
Future Directions: Prospective registries with adjudicated endocrine irAEs and biomarker profiling should test whether early endocrine surveillance and standardized replacement protocols improve survival and quality of life.
BACKGROUND: Immune checkpoint inhibitors (ICIs) are associated with various endocrine abnormalities. However, their underlying pathophysiology remains unclear. We investigated the effect of multiple endocrine abnormalities on the overall survival (OS) of patients treated with ICIs. METHODS: In total, 12,978 patients who received ICIs between 2014 and 2022 were investigated using the DeSC Japanese administrative claims database. Endocrine abnormalities were defined by each hormone replacement therapy, including levothyroxine, hydrocortisone, and insulin, in which it is difficult to distinguish central or primary hormone defect. Also, only patients with hypothyroidism after thyroiditis were included. Type 1 diabetes was additionally defined by the name of the disease and strict self-injection fees. Regression analyses were performed to identify risk factors for endocrine abnormalities and the effect of endocrine abnormalities on OS, adjusting for confounders including the number and duration of ICI administrations. RESULTS: Single and multiple endocrine abnormalities were observed in 12.0% and 1.4% of patients, respectively. The most common combination was hypothyroidism and adrenal insufficiency (1.3%). Kaplan-Meier analysis indicated better survival in patients with multiple and single endocrine abnormalities than in those without (P < .01). Multivariable analysis revealed lower mortality in patients with multiple and single endocrine abnormalities (adjusted hazard ratio [aHR] 0.39; 95% confidence interval [CI], 0.28-0.54, P < .01; aHR 0.65; 95% CI, 0.5-80.72, P < .01, respectively) than in those without. Mortality was significantly lower with multiple abnormalities than with single (aHR 0.56; 95% CI, 0.39-0.79, P < .01). CONCLUSIONS: The development of multiple endocrine abnormalities in patients treated with ICIs is associated with improved survival compared with that of patients with a single abnormality.
2. Association between steatotic liver disease and microvascular complications in individuals with type 2 diabetes: a cohort study in the UK Biobank.
In 25,630 adults with type 2 diabetes followed for a median of 12.1 years, steatotic liver disease (FLI ≥60) increased the risk of total microvascular complications (HR 1.15), particularly nephropathy (HR 1.20) and neuropathy (HR 1.46). Mediation analysis suggested that poor glycemic control accounted for about 22.5% of this association.
Impact: Provides robust prospective evidence that SLD independently augments microvascular risk in T2D beyond traditional factors, quantifying glycemic mediation and targeting high-risk stratification.
Clinical Implications: Screen for steatotic liver disease in T2D to refine risk stratification for nephropathy and neuropathy; intensify multifactorial management, including glycemic control, in those with SLD.
Key Findings
- SLD (FLI ≥60) was associated with higher risk of total incident microvascular complications (HR 1.15; 95% CI 1.04–1.27).
- Risks were elevated for diabetic nephropathy (HR 1.20) and neuropathy (HR 1.46), but not retinopathy (HR 1.05, non-significant).
- Poor glycemic control (HbA1c ≥7%) mediated approximately 22.5% of the SLD–microvascular complications association.
Methodological Strengths
- Very large prospective cohort with long follow-up (median 12.1 years).
- Use of Cox models and formal mediation analysis to quantify glycemic contribution.
Limitations
- SLD defined by fatty liver index may misclassify hepatic steatosis compared with imaging or biopsy.
- Residual confounding and outcome ascertainment limitations inherent to observational cohorts.
Future Directions: Validate findings with imaging-based SLD definitions and test whether targeted interventions in T2D with SLD reduce nephropathy/neuropathy incidence.
BACKGROUND: Cross-sectional studies have revealed that steatotic liver disease (SLD) is associated with prevalent diabetic microvascular complications, but longitudinal evidence in large samples is insufficient. We aimed to prospectively investigate the association between SLDs and the risk of microvascular complications in patients with type 2 diabetes (T2D), and to explore whether glycemic control played a mediating role in this association. METHODS: The population-based cohort, which was based on the UK Biobank study, included 25,630 T2D patients at baseline. SLD was defined as a fatty liver index ≥ 60. A glycated hemoglobin level ≥ 7% (53 mmol/mol) was considered poor glycemic control. The primary outcome was total incident diabetic microvascular complications, defined as the first occurrence of diabetic nephropathy, diabetic neuropathy, and/or diabetic retinopathy. The cox proportional hazard regression model was used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for diabetic microvascular complications. Mediation analysis was applied to explore whether the association between SLDs and diabetic microvascular complications was mediated by glycemic control. RESULTS: The mean age of the study participants was 59.6 years, and 58.1% of them were males. During a median follow-up period of 12.1 years, 5,171 participants were diagnosed with microvascular complications. Compared with non-SLD participants, SLD participants had a HR of 1.15 (95% CI: 1.04, 1.27) for total microvascular complications, a HR of 1.20 (95% CI: 1.06, 1.35) for diabetic nephropathy, a HR of 1.05 (95% CI: 0.91, 1.21) for diabetic retinopathy, and a HR of 1.46 (95% CI: 1.15, 1.86) for diabetic neuropathy. The results of the mediation analysis revealed that the mediating proportion of glycemic control in the association between the SLD group and total diabetic microvascular complications was 22.5% (95% CI: 10.4%, 91.0%). CONCLUSIONS: SLD was associated with an increased risk of microvascular complications, especially diabetic nephropathy and diabetic neuropathy, in T2D patients. Glycemic control partially mediated the association between SLDs and diabetic microvascular complications.
3. Detecting Hyperglycemia Using Biomarkers Versus Continuous Glucose Monitoring.
In 552 adults with diabetes, glycated albumin and fructosamine correlated strongly with CGM mean glucose and time-above-range metrics, comparable to HbA1c, whereas 1,5-AG performed weaker. Findings support glycated albumin and fructosamine as practical alternatives when HbA1c is unreliable.
Impact: Directly benchmarks common serum biomarkers against CGM metrics across a diverse cohort, informing laboratory selection for hyperglycemia assessment in conditions where HbA1c is inaccurate.
Clinical Implications: Consider glycated albumin or fructosamine to monitor hyperglycemia when HbA1c is affected by anemia, hemoglobinopathies, CKD, or recent glycemic changes; avoid relying on 1,5-AG alone.
Key Findings
- Glycated albumin (r=0.64) and fructosamine (r=0.64) correlated strongly with CGM mean glucose, comparable to HbA1c (r=0.72).
- Both biomarkers showed high c-statistics (0.85–0.94) for detecting target time in range and time above range, similar to HbA1c.
- 1,5-anhydroglucitol correlated weakly with CGM metrics (r=0.46), underperforming as a hyperglycemia biomarker.
Methodological Strengths
- Use of blinded CGM over up to two weeks provides objective glycemic phenotyping.
- Diverse cohort (older age, sex and racial diversity) enhances generalizability to real-world T2D populations.
Limitations
- Cross-sectional design precludes temporal inference and clinical outcome correlations.
- CGM wear was limited to ~2 weeks; biomarker performance over longer horizons was not assessed.
Future Directions: Prospective studies should test whether GA/fructosamine-guided care improves outcomes where HbA1c is unreliable and evaluate performance across CKD stages and hemoglobin variants.
OBJECTIVE: To evaluate the concordance of glycated albumin, fructosamine, 1,5-anhydroglucitol (1,5-AG), and hemoglobin A1c (HbA1c) with continuous glucose monitor (CGM) metrics of hyperglycemia and glycemic control in a diverse population of adults with type 2 diabetes. RESEARCH DESIGN AND METHODS: This was a pooled cross-sectional analysis of 552 adults, ages 30-97 years old, with diabetes. Participants wore a CGM for up to 2 weeks, and we evaluated the agreement between blood biomarkers (glycated albumin, fructosamine, and 1,5-AG) with CGM-defined metrics of hyperglycemia and glycemic control. RESULTS: Of the 552 participants (mean age 74 years, 53% women, 36% Black), the median of mean CGM glucose was 132 mg/dL, and participants spent on average 84% of their time in range (70-180 mg/dL). CGM mean glucose was strongly related to HbA1c (r = 0.72), glycated albumin (r = 0.64), and fructosamine (r = 0.64) but weakly related to 1,5-AG (r = 0.46). Results were similar for time above range (>180 mg/dL). Glycated albumin and fructosamine performed similarly to HbA1c in the detection of target time in and above range (c-statistics ranged from 0.85 to 0.94). CONCLUSIONS: Glycated albumin and fructosamine had similar associations with CGM-defined metrics of hyperglycemia compared with HbA1c. These three biomarkers performed similarly in the detection of time above range and in range. Our results provide evidence for the utility of glycated albumin and fructosamine as alternate measures of hyperglycemia.